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Abstract 
The immense costs in both financial terms and pre-clinical research effort that 
occur in the development of anti-cancer drugs are unfortunately not matched by a 
substantial increase in improved clinical therapies due to the high rate of failure 
during clinical trials. This may be due to issues with toxicity, or lack of clinical 
effectiveness when the drug is evaluated in patients. Currently, much cancer re-
search is driven by the need to develop therapies that can exploit cancer cell adap-
tations to conditions in the tumor microenvironment such as acidosis and hypoxia, 
the requirement for more-specific, targeted treatments, or the exploitation of ‘pre-
cision medicine’ that can target known genomic changes in patient DNA. The high 
attrition rate for novel anti-cancer therapies suggests that the pre-clinical methods 
used in screening anti-cancer drugs need improvement. This chapter considers the 
advantages and disadvantages of 3D organotypic models in both cancer research 
and cancer drug screening, particularly in the areas of targeted drugs and the exploi-
tation of genomic changes that can be used for therapeutic advantage in precision 
medicine. 
 
  
3 
Introduction 
The simple definition of “organoid” is “resembling an organ”, implying that it 
should contain more than one cell type that is typically found in the organ of its 
origin, demonstrate an organ specific function, and that the cells should show some 
degree of organization. However, given that in this case the “organ” being modelled 
is a tumor, most, if not all 3D models meet these criteria. 3D culture can encompass 
various types of model such as spheroids and organoids, (terms which are often used 
interchangeably), or explants. Arguably, xenografts are also a type of 3D culture 
that fits the tumor organoid definition. For sake of clarity, the various 3D systems 
meeting these criteria will be discussed here separately. For more information on 
the definition and historical perspective of organoid development, see Simian and 
Bissell 2017. 
Although extensive funding supports cancer research each year, the majority of 
novel drugs and therapies fail to translate into clinical practice due to lack of success 
in clinical trials, either because of deficiencies in clinical efficacy, or issues with 
toxicity (Petsko, 2010; Arrowsmith, 2011). Approximately one drug in 5,000 - 
10,000 tested will gain FDA approval, with attrition rates in oncology particularly 
high with only 5% of anti-cancer therapies successfully undergoing Phase I/II clin-
ical trials (Zamboni et al. 2012, Ocana et al. 2011). This is despite strong and sig-
nificant in vitro and in vivo preclinical data, suggesting that better pre-clinical meth-
odologies are required to identify new therapeutics (Kamb, 2005; Caponigro et al. 
2011; Singh and Ferrara 2012; Siolas and Hannon 2013). The assessment of novel 
effective anti-cancer compounds is a compromise between the use of high through-
put, low cost testing strategies, and high cost, low throughput methods which may 
give better translational results.  
Most preclinical studies into the efficacy of anti-cancer drugs use cancer cell 
lines to assess various parameters such as cell survival, proliferation, cell death, 
migration and invasion. 2D cultures are one of the most cost effective strategies for 
high throughput assays and are used to test large numbers of compounds and select 
those for further examination. These cell lines can be exploited to investigate the 
role of specific pathways, genes or molecules using technologies such as CRISPR 
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(Sander and Joung 2014; Ledford 2015), siRNA (Moore et al. 2010), or inducible 
transgenics (Pajic et al. 2000; Belteki et al. 2005; Saunders 2011; Xie et al. 2014). 
However, these systems lack the heterogeneity of the original tumor, since cell cul-
ture selects those clones that best proliferate and survive in culture conditions (Dan-
iel et al. 2009; Hensley et al. 2016). Using a panel of cell lines of the cancer of 
interest, or from different tumors such as the NCI-60 panel, or the de novo expan-
sion of cell lines from tumor tissue, can partially overcome this problem (Burdall et 
al. 2003; Langdon 2004); but 2D culture cannot replicate the complex stromal ele-
ments of tumors, interactions with immune cells, inflammatory mediators, growth 
factors or the acidic/hypoxic conditions found in the tumor microenvironment 
(TME) (Karar and Maity 2009; Hanahan and Weinberg 2011; Ward et al. 2013). 
Targeting the adaptations cancer cells adopt to survive in the tumor microenviron-
ment, is currently a novel approach to the treatment of solid tumors, and more ap-
propriate models are required to support this research (McAllister and Weinberg 
2010; Pettersen et al. 2015). 
 
3D in vivo models 
a) Mouse xenografts 
Following assessment in 2D model systems, candidate compounds move into in 
vivo studies: generally mouse xenografts growing human tumor cell lines in strains 
of immunocompromised mice. These have shown mixed efficacy in translating 
novel drugs into clinical use, and often reproducibility of results is poor (Sausville 
and Burger 2006; Boedigheimer et al. 2013); but they do allow in vivo monitoring 
of tumor growth, drug toxicity, efficacy and pharmacokinetic studies, and will re-
flect the oxygen and pH gradients found in solid tumors. However, some cell lines 
do not form xenografts, metastatic models are limited, and immune responses, 
which affect tumor growth are compromised. Although xenografts incorporate 
some stromal elements, they are murine rather than human (Daniel et al. 2009). 
Xenografts are selected for rapidity of growth, while human tumors can take years 
to progress clinically; therefore these models do not replicate the heterogeneity of 
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the original tumor.  Many xenografts are implanted subcutaneously and therefore 
do not reproduce the specific microenvironment of the tumor under investigation 
(Polilti and Pao 2011). Orthotopic xenografts enable tumor development in the or-
gan of origin, this can allow evaluation in a preclinical tumor model which more 
closely mimics the disease process in humans. However these models can be more 
difficult to establish compared with subcutaneous implantation. 
 
b) Genetically engineered mouse models (GEMMs) 
Spontaneous or carcinogen generated tumors, reflect the stromal interactions and 
angiogenesis found with tumor progression, but in a murine system with functioning 
immune responses. In GEMMs, tumors originate in a group of cells as a conse-
quence of germline or somatic mutations, and share the genetic heterogeneity and 
histopathology of human tumors. They allow expression of oncogenes in a tissue-
specific manner as well as conditional expression or deletion of oncogenes and tu-
mor suppressors, allowing many cancers to be modelled (Sharpless and Depinho 
2006; Politi and Pao 2011). GEMMs are also useful to model treatment resistance, 
chemotherapy enhancement, co-treatments and biomarker validation (Pietras and 
Hanahan 2005; Bell-McGuinn et al. 2007; Faca et al. 2008; Pitteri et al. 2009; 
Bellmunt et al. 2010; Polti et al. 2010). Several studies show that GEMMs model 
both the TME and stroma more accurately than xenografts (Olive et al. 2009; 
Graves et al. 2010), and better replicate the sensitivity of cancer to systemic therapy 
in clinical trials (Singh et al. 2010; Chen et al. 2012). However, the model is still 
murine. 
 
c) Patient-derived xenografts (PDXs) 
PDXs, involving the transfer of patient-derived tumor tissue into immunocom-
promised mice, (Kopetz et al. 2012; Julien et al. 2012; Huang et al. 2014), show 
pathology, growth and metastatic outcomes that closely correspond to the original 
tumor, and sustain the original histological markers, gene expression profiles, and 
proliferation indices (DeRose et al. 2011; Dean et al. 2012; Tentler et al. 2012; 
Stewart et al. 2017). This means that experimental data can be complemented with 
6  
clinical information, such as response to treatment in the original patient. The use 
of PDXs is increasing in preclinical studies (Hidalgo et al. 2011; Tentler et al. 2012), 
in conjunction with ‘co-clinical trials’ which run preclinical PDX and clinical trials 
at the same time (Nardella et al. 2011). For example, one study demonstrated that 
PDXs developed from individual patient tumors could be used to select treatment 
options with an 88% response rate (Hidalgo et al. 2011). PDXs have also been used 
to model human phase II trials that can examine differences in therapy responses 
across different cancers (Townsend et al. 2016; Byrne et al. 2017). PDX models 
have now superseded the NCI-60 panel as the gold standard for cancer research 
because of the preservation of heterogeneity (Leford, 2016). 
Whilst this system is more robust, PDXs do have some shortcomings. Passaging 
is time consuming and some human stromal tumor elements are progressively lost 
over time. The rate of engraftment is poor for some cancer types such as prostate 
and ER+ breast cancer (DeRose et al. 2011; Lawrence et al. 2013) and tissue from 
needle biopsies is often inadequate for growth. There is still deficiency in immune 
responses and increased growth rate of tumors compared with human cancers 
(Rayal et al. 2012; Huang et al. 2014), although tumor growth and drug validation 
in these models can take several months (Hildalgo et al. 2011; Gao and Chen 2015). 
The same tumor sample can produce PDXs which may differ in genetics, or cell-
surface markers, depending on the mouse strains used for tumor growth (Klco et al. 
2014). The ratio of cancer cells to stromal cells can also drift; for example, pancre-
atic ductal adenocarcinomas (PDAs), contain high numbers of stromal cells 
(Guillaumond et al. 2013; Beloribi-Djefaflia et al. 2015; Delitto et al. 2015), but 
because cancer cells multiply at a greater rate than stromal cells, stromal/cancer cell 
interactions change as cell ratios change (Martinez-Garcia et al. 2014). A recent 
study of 1,100 PDX models across 24 types of cancer showed sizable phenotypic 
and genomic changes between the progression of PDX models and human cancers, 
with PDXs developing both chromosome and gene copy number alterations during 
passages (Ben-David et al. 2017), which could influence the response to drug treat-
ment. Metabolic reprograming has been identified as a key hallmark of cancer 
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(Hanahan and Weinberg 2011), leading to increased interest in targeting specific 
enzymes as a novel therapeutic strategy in this disease. However, studies using hu-
man lung cancer tissue, show that both glycolysis and glutaminolysis are increased 
when human lung tumor tissue is cultured in PDX models (with murine stroma) 
when compared with the same tissue cultured with human stroma (using tissue 
slices), implying that PDX models may not be predictive of patient responses in the 
context of drugs which target tumor metabolism (Lane et al. 2016). 
PDXs are not suitable for high throughput screening, or genetic manipulation 
(Gao and Chen 2015), but are extremely useful in situations where primary tumor 
material is scarce or rare, allowing long-term culture of much more diverse and 
heterogeneous tumor samples (Zhang et al. 2013). They can be developed from 
treatment resistant or recurrent tumor tissue (Aparicio et al. 2015; Townsend et al. 
2016; Stewart et al. 2017), allowing the mechanisms involved to be explored. Var-
ious depositories of diverse treated/untreated tumor PDXs have been produced or 
are being developed, (EuroPDX consortium, the Public Repository of Xenografts, 
and the National Cancer Institute Patient-derived Models Repository) some of 
which are open source, such as that provided by Stewart et al., encompassing pedi-
atric solid tumors, from 168 patients and 12 cancer types (Klco et al. 2014; Gao et 
al. 2015; Stewart et al. 2017; Townsend et al. 2016; Bruna et al. 2016). 
 
d) Improving animal models 
Animal models have been improved by ‘humanizing’ some aspects of the host, 
introducing human stromal elements or immune cells and thus humanizing the TME 
to some extent and allowing new immunotherapies to be explored  (Proia, 2006; 
Vudattu et al. 2014; Morton et al. 2016). Such methods have been used to engineer 
the primary tumor environment, or mimic metastatic niches in breast and prostate 
cancers (Wang et al. 2010; Thibaudeau et al. 2014; Hesami et al. 2014; Holzapfel 
et al. 2014).  One group has reported humanizing immunocompromised mice using 
aspirated hematopoietic stem and progenitor cells from bone marrow biopsies taken 
from cancer patients (Werner-Klein et al. 2014). However, the main obstacles to the 
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use of animal models remain high cost and low throughput. The pros and cons of 
these animal models are outlined in Table 1. 
 
3D in vitro models 
Xenograft models can have long latency periods; PDXs are maintained in a mu-
rine host and the availability and access to fresh human tumor tissue is a limiting 
factor for many researchers. Further, the trend in ethical research is to try to limit 
the use of animals wherever possible. There is therefore, a strong need for low cost, 
high throughput, clinically and physiologically relevant models for cancer research. 
Several studies have illustrated that 3D gene signatures can predict prognosis in 
several independent datasets (Fournier et al. 2006; Martin et al. 2008), suggesting 
that 3D in vitro ‘organoid’ models may help bridge the gap between pre-clinical 
translation and clinical trials.  
Cancer stem cells (CSCs) form a subpopulation of cancer cells within a tumor 
that have been attributed with the ability to initiate primary, metastatic and recurrent 
tumor growth, and to be involved in treatment resistance (Mitra et al. 2015; Bomken 
et al. 2010). These cells have become an obvious focus for anti-cancer research. 
Tumor spheroids and organoids (see below) are both enriched for populations of 
CSCs (Lancaster and Knoblich 2014; Ishiguro et al. 2017; Capodanno et al. 2018). 
This allows for fast expansion of both organoid and spheroid culture systems, once 
the initial population of these 3D structures has been established.  Further, both of 
these models can be used to harvest CSCs for research purposes (Ishiguro et al. 
2017; Wang et al. 2018); an improvement on the traditional methodology for isola-
tion and enrichment of these cells. CSCs from other mammals, for example from 
canine cancers, can also be obtained from this approach aiding studies in compara-
tive and veterinary oncology (Capodanno et al; 2018).  
a) Spheroids  
Many cancer cell lines can be grown as small avascular spheroids using 3D scaf-
folds, hydrogels/collagen gels, or suspension culture as illustrated in Figure1 
(Frederich et al. 2009; Li and Lu 2011, Verjans et al. 2017). These generate a more 
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physiological model for cancer drug testing, displaying increased heterogeneity, 
cell-cell and cell-extracellular matrix (ECM) interactions, and differential gene/pro-
tein expression in comparison with monolayer cultures (Yamada and Cukierman 
2007, Loessner et al. 2010). Drug and cell signaling responses differ when 3D and 
2D methodologies are evaluated (dit Faute et al. 2002; Yamada and Cukierman, 
2007; Loessner et al. 2010; Ravi et al. 2014). For example, in SKBR-3 breast cancer 
cells, the HER2 and HER3 receptors heterodimerise in 2D cultures, but HER2 forms 
homodimers in spheroids, with an increased response to HER2 inhibition (Pickl and 
Ries 2009). 3D cultures of human pancreatic, ovarian, liver and lung cancer cells 
exhibit increased chemoresistance in contrast to 2D culture via mechanisms that 
involve interactions with the ECM/TME (Sethi et al. 1999; Loessner et al. 2010; 
Longati et al. 2013; Ekert et al. 2014). 
In solid tumors, rapid cell growth induces gradients of hypoxia and acidosis to 
develop, affecting sensitivity to radiation and chemotherapy (Gatenby et al. 2007; 
Correia and Bissell 2012; Ward et al. 2013). Although spheroids are grown under 
atmospheric oxygen tensions they develop O2, CO2, pH and metabolite gradients as 
they reach approximately 400 – 600 uM in size, modelling the biology of solid tu-
mors as illustrated in Figure 1 a and b. (Minchinton and Tannock 2006; Poussegur 
et al. 2006; Friedrich et al. 2009). These 3D models are now a necessity, particularly 
since novel treatment approaches targeting both pHi regulation and/or glycolysis in 
hypoxic tumors are expected to be useful in combination with systemic and/or ra-
diation therapy (Riffle et al. 2017). One reason for translational drug failure may be 
the lack of exploration of the effects of new drugs in conditions found in the TME. 
Spheroids can be produced from cancer cells adapted by CRISPR, siRNA, 
shRNA or inducible transgenics and can incorporate other cell types such as fibro-
blasts or be embedded in ECM proteins to examine cell-cell and cell-matrix inter-
actions, migration and invasion (Schmeichel and Bissell 2003; Heneweer et al. 
2005; Hsiao et al. 2009; Ingram et al. 2010; Herrmann et al. 2014; McCracken et al. 
2014; Ward et al. 2015) (Figure 2a). For example, the leading edge of pancreatic 
cancer cells contain RhoA-dependent projections which can be targeted by anti-
metastatic treatments; these were first identified in 3D culture models (Timpson et 
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al. 2011). Tumor-derived human and murine breast cancer spheroids embedded into 
collagen, showed that cells expressing basal epithelial markers lead to collective 
invasion, both in 3D culture and in in vivo studies across breast cancer sub-types 
(Cheung et al. 2013). 
Co-culture of spheroids and cancer-associated fibroblasts (CAFs) demonstrated 
that CAFs influence treatment resistance and invasion (Crawford et al., 2009; Li 
and Lu 2011; Horie et al. 2012; Straussman et al. 2012; Clark et al. 2013; Jaganathan 
et al. 2014; Kim et al. 2015). Co-culture systems have been used to replicate the 
metastatic niche of prostate cancer cells in bone using co-culture with osteoblasts 
and endothelial cells (Hsiao et al. 2009). Other 3D co-culture systems, using niches 
from lung or bone marrow stroma, demonstrated the role of TSP1 in tumor dor-
mancy (Ghajar et al. 2013), while the relationship between brain endothelial cells 
and cancer stem cells have been examined in glioblastoma using 3D models of the 
perivascular niche (Infanger et al. 2013). A 3D co-culture of pancreatic stellate cells 
with PDA cells has produced a model that could be used to investigate PDA-stroma 
interactions in high throughput assays for drug screening (Ware et al. 2016). Sphe-
roid generation using a defined size microwell assays with non-adherent hydrogels 
can generate uniform spheroids from cervical, breast, and head and neck squamous 
cells carcinoma cells within 3 to 6 days (Singh et al. 2015, 2016), making this sys-
tem useful for high throughput assays. 
b) Organoids 
Organoids are created by culturing tissue samples with factors to stimulate the 
replication of pluripotent stem cells. It can take 3 weeks for organoids to grow to 
approximately 1 mm3 at which stage they contain the major cell types of the original 
tissue (Lancaster and Knoblich, 2014). Tumor organoids can be developed from 
tumor tissue or from isolated CSCs, and replicate many of the features of the pri-
mary tumor. For example, glioblastoma organoids from patient-derived CSCs 
demonstrated heterogeneity, a proliferative outer rim surrounding a hypoxic interior 
of senescent cells with dispersed quiescent radioresistant CSCs. Tumors generated 
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from these patient-derived organoids, showed the histological features of the paren-
tal tumor (Hubert et al. 2016).  
Organoids can also be developed from murine tumor models.  These have been 
used to explore the role of -catenin and PI3K in colorectal cancer; a screen of 
inhibitors using this system associated 4EPB1 and Akt with cellular survival and 
motility in disease progression (Riemer et al. 2017). They have been developed 
from resected tissue and biopsies from colorectal (CRC) and prostate cancer, breast 
cancer, PDA, liver cancer, metaplastic epithelia from Barrett’s esophagus, and also 
from circulating tumor cells (Sato et al. 2011; Gao et al. 2014; Boj et al. 2015; 
Weeber et al. 2015; Broutier et al. 2017; Schutte et al. 2017, Sachs et al. 2018). 
Tumor organoids contain differentiated cell types, are biologically stable, can be 
frozen for later use and expanded once established (Sato et al. 2011; Sachs and 
Clevers 2014). Organoids allow the culture of tumors from individual patients, 
while maintaining the genetic and morphological diversity found within the corre-
sponding patient tumor (van de Wetering et al. 2015; Weeber et al. 2015; Broutier 
et al. 2017; Pauli et al. 2017); for example, CRC organoids displayed a high degree 
of genetic similarity with the tumor tissue of origin (Schutte et al. 2017). PDA or-
ganoids generated from different stages of the cancer accurately replicated tumor 
progression based on transcriptomic and proteomic analysis (Boj et al. 2015) and 
demonstrated little change in histology, morphology, cytology or expression of dif-
ferentiation markers from the originating tumor after 16 days in culture (Huang et 
al. 2015). It remains to be established whether these similarities are sustained long 
term. Although several studies suggest that mutation patterns are maintained during 
multiple passages (van de Wetering et al. 2015; Weeber et al. 2015; Fujii et al. 2016; 
Pauli et al. 2017; Schutte et al. 2017), one study using fluorescent markers showed 
that one color pre-dominated after 30–40 days in culture, suggesting clonal drift 
over time (Fujii et al. 2016). Organoids can also provide tissue for the study of rare 
cancers or those where cell line models are scarce. A further advantage is that con-
trol organoids from the same patient, can be developed from tumor-adjacent tissue. 
Several groups have reported the culturing of matched normal and tumor organoids 
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from treatment naïve surgical resections or biopsies (Boj et al. 2015; Van de Weter-
ing et al. 2015). 
Organoid cultures still lack tumor stroma, vasculature and immune cell interac-
tions and those derived from early stage cancers appear to grow more quickly; there-
fore more malignant tumors may need optimized conditions for growth. They will 
not mirror the accumulated genetic mutations found in later stages of progression if 
developed from early stage tumors, but drug treatments should allow generation of 
treatment resistant models. This methodology may lead to personalization of drug 
testing for a plethora of cancers (Sachs and Clevers 2014), but the length of time for 
growth can vary depending on the cancer type. Costs may be also an issue and it is 
still unclear whether this method is applicable to all epithelial cancers. 
Some of these issues are overcome by marrying organoid and PDX methodol-
ogy. In one PDA model, tumor organoids were grown in orthotopic sites in mice, 
where they formed early-grade tumors that could develop and progress from local 
invasion to metastasis, while maintaining the histology of the original tumor tissue 
(Boj et al. 2016). This methodology was used to characterize specific alterations 
between pre-malignant and malignant states using transcriptomic and proteomic 
studies. Organoids grown from normal tissue, can be genetically engineered, using 
technologies such as CRISPR and therefore manipulated to study specific cancer 
mutations and cancer development and metastasis (Dekkers et al. 2013; Schwank et 
al. 2013; Matano et al. 2015; Fujii et al. 2016; Drost et al. 2017; Roper et al. 2017). 
As with spheroids, other cell types can be cultured with organoids. For example, 
co-culture of intraepithelial lymphocytes with murine intestinal organoids, showed 
lymphocytes entering and leaving organoids (Nozaki et al. 2016), but better tumor 
models will be achieved with the co-culture of stromal elements, particularly in tu-
mors such as PDA, where the stroma is particularly important. 
Organoids have been extremely useful in the study of some types of cancer. For 
example, de novo prostate cancer cell line culture is difficult, with only seven widely 
available cell lines that lack expression of many of the genetic lesions involved in 
this cancer. Using organoids from prostate cancer patients showed that they devel-
oped similarities to the histology of the original tumor, and contained many of the 
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mutations in SPOP, and FOXA1 as well as CHD1 loss, which are known to be in-
volved in prostate cancer (Gao et al. 2014). Further these organoids demonstrated 
differences in responses to drugs and after 3 months culture, the organoid lines were 
shown to still share matching somatic mutations and transcriptomes with the origi-
nal tumor. Organoids have been also been established from rare CRC tumors in-
cluding neuroendocrine cancers and serrated adenomas, and grown from biopsies 
from metastatic disease and from circulating tumor cells (Gao et al. 2014; Yu et al. 
2014, Fujii et al. 2016). 
CRC organoids responded to drug treatment based on the molecular status of the 
original tumor (Gao et al. 2014; Van de Wetering et al. 2015). Screening of 83 drugs 
in these organoids confirmed that TP53 loss of function mutants did not respond to 
the MDM2 inhibitor nutlin 3a, nor RAS mutants to EGFR inhibitors and demon-
strated responsiveness of RNF43 mutants to inhibitors of Wnt secretion. Organoids 
generated from liver metastases were more metastatic in xenograft culture even 
though the gene expression and mutational status were found to be comparable with 
the original tumor (Van de Wetering et al. 2015). Comparisons between a primary 
gastric cancer and its ovarian metastatic growth, found that the metastasis lost am-
plification of the FGFR2 gene, but had gained alteration in transforming growth 
factor- receptor 2 (Nadauld et al. 2014). Other research illustrated that combina-
tion treatment using pan-HER and MEK inhibitors caused cell-cycle arrest in 
KrasG12D mutant CRC organoids, but cell death in KRAS wild-type organoids; com-
bining this treatment with BCL-2 inhibition, surmounted this resistance, a result 
counter to those seen in cell lines (Verissimo et al. 2016). Screens of single com-
pounds or co-treatments in CRC, endometrial and uterine cancer organoids have 
uncovered several possible original treatment strategies (Pauli et al. 2017).  
A large multicentre, prospective trial (TUMOROID – NL49002.031.14) is as-
sessing whether the drug responses of organoids can be used to evaluate treatment 
responses in metastatic CRC, breast or NSCLC patients. The use of organoids in 
patient selection for clinical trials is under examination in the SENSOR study 
(NL50400.031.14 EudraCT 2014-003811-13), using biopsies from metastatic CRC 
and NSCLC. This is of importance since it is likely that potential novel treatments 
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could fail if evaluated in an inappropriate patient group which is of real concern in 
the development of specific, targeted therapies. There are several initiatives to de-
velop both cancer and normal organoids as resources for researchers. For example, 
the Hubrecht Organoid Technology (HUB) biobank, which forms a section of the 
Human Cancer Models Initiative, aims to generate around 1,000 models in collab-
oration with The National Cancer Research Institute, Cancer Research UK, and the 
Wellcome Trust Sanger Institute. This initiative develops and analyses tumor or-
ganoids from pancreatic, prostate, breast, CRC and lung tumors, collating patient 
data and drug sensitivity. It was recently reported that over 100 breast cancer or-
ganoids from primary and metastatic tumours have also been cultivated (Sachs et 
al. 2018).   
c) Tumor Explants 
Tumor explants are a type of organoid derived from small tumor fragments often 
cultured on a semi-solid support (Figure 2b). Using primary tumor tissue in ex vivo 
culture maintains the stromal components of the tumor and the tumor architecture 
(van der Kuip et al. 2006; Gu et al. 2013a; Witkiewicz et al. 2015; Karekla et al. 
2017). 
Cultured explants offer a route towards precision medicine because multiple 
drug responses can be identified and monitored within days (Ward et al. 2015), a 
far more acceptable time scale in comparison with PDXs or organoids. Ex vivo tu-
mor explants using naive biopsy tissue could provide analogous insights to neoad-
juvant clinical trials, to verify responsiveness of the primary tumor to specific ther-
apies, and could be used to examine novel therapies, co-treatments, and treatment 
scheduling. Explants can survive for over a month in culture, (Leeper et al. 2011; 
2012; Katz et al. 2012; Ward et al. 2015); they reflect the heterogeneity of the tumor 
structure, are a good model to target microenvironmental adaptations and can allow 
comprehensive testing of pre-clinical models in heterogeneous tumor material sub-
types. If tumor growth recurs, post-treatment resistance in individual patients can 
be investigated if tumor tissue is available.  One of the difficulties in modelling 
breast cancer is the heterogeneity of the disease as observed in the clinic, since 
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breast cancer subtypes often show differential responses to therapies. Ex vivo cul-
ture of unselected breast tumor explants can overcome this difficulty. Studies show 
that explanted breast tumor tissue conserved ER, PR and HER2 status and prolifer-
ation rates in comparison with the original primary tumor tissue, which demon-
strates the preservation of many characteristics of the original tumor in the ex vivo 
model (Dean et al. 2012). Tumor explants have also been used to examine novel 
carbonic anhydrase inhibitors in breast and topical chemotherapy in urothelial car-
cinoma (Bolenz et al. 2009; Ward et al. 2015). 
Studies using human breast tumor explants illustrated that inhibitors of Rac 
GTPases (EHT 1864), and STAT3 (Stattic) could prevent spread of breast cancers 
and cell proliferation at the invading edge of a tumor (Katz et al. 2012). In other 
work, treatment of breast cancer explants with the CDK4/6 inhibitor, PD-0332991 
showed suppression of proliferation as measured by Ki67 staining, in all but a small 
subset of explants resistant to treatment. In these resistant tumors, lymph node me-
tastases were also unaffected by treatment, and further research demonstrated that 
this was linked to the lack of the retinoblastoma (RB) tumor suppressor protein 
(Dean et al. 2012). 
PD-0332991 has also been examined in PDA tumor explants (Witkiewicz et al. 
2015). The CDK4/6 inhibitor, p16ink4a is commonly lost in PDA, but in most mod-
els and in xenografts, inhibition of CDK4/6 is a fairly ineffective treatment and re-
sistance quickly develops. In the explant model, however, CDK4/6 inhibition sup-
pressed proliferation in all explants tested, except for one demonstrating loss of RB; 
a result mirrored in PDX of the same tumors, modelled in parallel (Witkiewicz et 
al. 2015), suggesting differential drug responses across systems. A study in prostate 
cancer explants using the Jak2 inhibitor AZD 1480 (Gu et al. 2013b), demonstrated 
that responsive explants underwent apoptosis when nuclear Stat5a/b decreased in 
response to the inhibitor, while in resistant explants, it did not. Prostate tumor ex-
plants have also been used to test the effectiveness of novel Stat5a/b inhibitory com-
pounds (Liao et al. 2015) 
Explants have been used to examine the links between metabolism, hypoxia and 
inflammation in Barrett esophagus, a preneoplastic lesion which can progress to 
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esophageal adenocarcinoma (Phelan et al. 2016), and to examine the role of bile 
acids in gastroduodenal reflux which causes increased expression of MUC1, asso-
ciated with early carcinogenic changes in this condition (Mariette et al. 2008). They 
have also been used in head and neck cancer to study the effectiveness of a phyto-
chemical treatment, Lupeol (Bhattacharyya et al. 2017). Results showed a good re-
sponse to Lupeol, and using explants from a cisplatin-resistant tumor, it was found 
that this molecule could resensitize the tumors to cisplatin (Bhattacharyya et al. 
2017). In non-small cell lung carcinoma, tumor explants could be used to predict 
patient response to therapy and to monitor clinically relevant biomarkers (Karekla 
et al. 2017). Explants have been used to confirm and investigate changes between 
low and high grade tumors in several settings such as endometrial cancer (Cornel et 
al. 2012). Analysis of sarcoma development suggests that while the p53 tumor sup-
pressor pathway may be intact, the p53 ubiquitin ligase, MDM2, is often amplified 
or overexpressed (Toledo and Wahl 2006). Although pre-clinical studies in cell 
lines with amplification of MDM2 using the MDM2 inhibitor Nutlin-3a produced 
positive results, only 1 patient in 20 showed a partial response in clinical trials in 
sarcoma patients (Muller et al. 2007; Ray-Coquard et al. 2012). Pishas et al. used 
sarcoma tumor explants from a range of subtypes and showed that there was no 
correlation between MDM2 amplification and response to Nutlin-3a (Pishas et al. 
2013) and that non-responsiveness to the drug was conferred by hypermethylation 
of the p53 target gene GADD45A. Explants have also been used in radiation studies. 
For example, the effectiveness of inhibiting TGF- as a treatment or possible radi-
osensitiser of high grade glioma has been examined in tumor explants (Bayin et al. 
2016). Results showed that most, but not all high grade gliomas, were responsive, 
and the authors suggest, that tumor explants could provide a rapid platform to de-
termine patient response to this therapy and stratify treatment. 
Currently, the main in vivo methodology for studying metastasis, generally in-
volves the use of mouse models. Culture of tumor explants enables invasive changes 
in an appropriate TME to be assessed and novel therapeutics to be analyzed in pa-
tient samples in a fast and quantitative format (Ward et al. 2015) (Figure 2b). The 
effect of different ECM components and stromal cells can also be evaluated and 
17 
monitored in this system. The main benefits of explants in these assays are that 
growth/response/invasion can be monitored continuously and appraised at any time 
over the course of an experiment and after use the explant tissue can be fixed and 
analyzed. 
Normal skin explants are being used to investigate tumor immunology and pos-
sible anti-tumor vaccination development. One strategy currently used is to load 
dendritic cells with tumor associated antigens, but the costs of generating these cells 
and treating them is extremely high. The use of skin tissue explants to load resident 
dendritic cells with tumor antigens in situ, has been successfully explored as an 
alternative method (Ruben et al. 2014). Immune checkpoint inhibition has demon-
strated promise in several malignancies, but successful treatment is dependent on 
infiltration of CD8+ T cells. Prostate tumor explants were successfully treated to 
increase numbers of CD8+ T cells while decreasing numbers of immune suppressor 
cells, (Muthuswamy et al. 2016), illustrating their use in investigation of immuno-
therapeutic strategies. At present, one drawback of tumor explants is the lack of 
vascularization which prevents study of angiogenesis and its inhibitors. However, 
novel research into vascularization of tumor explants has been recently published 
(Bazou et al. 2016). This group has developed a method of inducing vasculature 
formation into xenografts of human breast cancer and melanoma, ex vivo, and con-
sider that it should be possible to adapt this methodology for vascularization of hu-
man tumor explants. The advantages and disadvantages of 3D in vitro organoid sys-
tems are listed in Table 2. 
Conclusions 
It has been estimated that over 90% of drugs that make it through to clinical trials 
fail because of lack of efficacy and concerns over safety (Townsend et al. 2016, 
Ledford, 2011). Given the particularly high attrition rate of novel anti-cancer ther-
apies during progression from pre-clinical to clinical trials, it is obvious that current 
testing methodologies are problematic. Better, more physiological systems are 
clearly needed for a) drug testing and b) patient participation in an era of more tar-
geted treatments and personalized medicine. The ‘ideal’ tumor model would be able 
to mimic the development of malignant cells, angiogenesis, stromal development, 
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immune responses, metastasis, therapeutic efficacy, and progression to resistant dis-
ease. This chapter shows that there is not one specific methodology that can fulfil 
these criteria. Therefore more than one model system will be required to provide 
better translational results.  
Cell lines are a suitable model for drug screening, but lead compounds need to 
be tested in more intricate animal models, that allow for pharmacokinetic and tox-
icity studies that can monitor off target effects. These in vivo models are useful, and 
GEMMs and PDXs can reflect many of the features of the tumor from which they 
were developed. But the time taken for tumor growth is not compatible with use as 
a clinical decision making tool in precision medicine. However, in vitro models 
specific to an individual patient (such as organoids or tumor explants), can be used 
to test drugs and guide treatment in a more specialized manner. Results from these 
systems are available within days and could thus prevent the use of ineffective drugs 
for a given patient and limit access to more expensive drugs to those likely to ben-
efit.   
Access to human tumor tissue is problematic for many scientists, but because 
organoids can be stored they can be used as a research resource and passed to other 
researchers. Organoids could also be developed from GEMM mouse models and 
used in cancer research. They would be particularly useful in the study of the pre-
clinical stages of cancer, and in the study of cancer resurgence from residual disease.  
This methodology has been used to study recurrence in breast cancer, and showed 
that these residual cells develop to become transcriptionally divergent from both the 
original tumor and normal epithelium (Havas et al. 2017). Organoids can be used 
for high throughput drug screening assays that meet industry standards (Huang et 
al. 2015; Van de Wetering et al. 2015; Boehnke et al. 2016). 
The most significant factor that is likely to govern the rate of success in oncology 
clinical trials, is matching the experimental models to the clinical malignancy. The 
pros and cons of experimental systems suggest that new therapeutics should be ex-
amined using several methods.  
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Table 1                                      
 
 
                                                         
 Strengths Weaknesses 
 
Mouse Xenografts 
- allow in vivo moni-
toring of tumor 
growth, drug toxicity 
and efficacy 
- reflect in vivo pH and 
oxygen gradients 
- limited metastatic 
models 
- compromised im-
mune responses 
- murine stromal ele-
ments 
 
 
GEMMs 
- share the genetic het-
erogeneity and histo-
pathology of human 
tumors 
- replicate both the 
TME and stroma 
more accurately than 
xenografts 
- model is still murine 
 
 
 
PDXs 
- pathology, growth 
and metastatic out-
comes closely corre-
spond to the original 
tumor 
- preserve the hetero-
geneity of different 
cancers 
- useful in cases where 
primary material is 
rare 
- availability/access to 
fresh tumor tissue is a 
limiting factor 
- passaging is time 
consuming 
- stromal tumor ele-
ments lost over time 
- rate of engraftment is 
poor for some cancer 
types 
- deficiency in immune 
response 
 
 
 
Table 1  
Listing the advantages and disadvantages of in vivo tumor models.  
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Table 2   
 
                                                                                               
 Set-up Methods Strengths Weaknesses 
 
Spheroids 
Spheroids are set up 
using cancer cell 
lines from 2D cul-
ture. (various meth-
ods are illustrated 
in Figure 1). These 
can be grown from 
genetically modi-
fied cells and can 
incorporate other 
cell types 
- exhibit cell/cell and 
cell/ECM interac-
tions 
- mimic in vivo oxy-
gen, pH and meta-
bolic gradients 
- useful in high-
throughput drug 
screening assays 
- use cancer cell 
lines, which can 
lose the biological 
traits of the can-
cer from which 
they derived 
 
Organoids 
Organoids are de-
veloped from tissue 
samples/cancer 
stem cells and con-
tain the cell types 
found in the tissue 
of origin. These 
cells can be genet-
ically modified, and 
cultured with other 
cell types 
- biologically stable 
- can be frozen for 
later use 
- allow the culture of 
tumors from individ-
ual patients 
- can provide tissues 
for the study of rare 
cancers or where cell 
line models are 
scarce 
- useful in high-
throughput drug 
screening assay 
- clonal drift may 
occur over time 
- high costs 
- lack tumor 
stroma, vascula-
ture and immune 
cell interactions 
 
Explants 
Explants are de-
rived from human-
tumor tissue – usu-
ally biopsies. 
Genetic modifica-
tion is difficult, but 
they can be cultured 
with other cell 
types 
- maintain the stromal 
components and tis-
sue architecture of 
the primary tumor 
- good model to target 
microenvironmental 
adaptations 
- maintain histology 
and proliferation 
rates of the original 
tumor 
- growth/response/in-
vasion can be moni-
tored continuously 
- lack of vasculari-
zation prevents 
the study of angi-
ogenesis and its 
inhibition 
Table 2  
Listing the advantages and disadvantages of 3D in vitro tumor models.  
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Figure Legends 
 
Figure 1.  Illustrating the physiological features of spheroids and several of the 
methods used to culture them. a) a schematic diagram of the different layers of a 
spheroid culture b) shows immunohistochemical staining for carbonic anhydrase 
IX, which is upregulated by hypoxia and indicates the hypoxic region c) spinner 
flask spheroid culture d) alginate culture e) hanging drop method. 
 
 
Figure 2. Illustrating 3D invasion assays using human breast cancer cell sphe-
roids and human breast cancer tumor explants. a) spheroids grown in spinner flasks 
and embedded in collagen I. Images were obtained at 0 h and 96h of culture. b) 
tumor explants prepared by trimming fat from biopsy samples and cutting into 
pieces approx. 1mm3, before embedding in collagen I. Images were obtained at 0h  
and 120h of culture. Images were acquired using phase contrast microscopy. Orig-
inal magnification x 25. 
 
 
